Literature DB >> 2466471

Adjuvant and neoadjuvant vincristine, bleomycin, and methotrexate for inguinal metastases from squamous cell carcinoma of the penis.

G Pizzocaro1, L Piva.   

Abstract

In a pilot study 12 patients with radically resected inguinal lymph node metastases from carcinoma of the penis and 5 patients with fixed inguinal nodes were treated with 12 weekly courses of vincristine, bleomycin and methotrexate (VBM). Only 1 of the 12 cases treated with adjuvant VBM relapsed after a median follow-up period of 42 months (range 18-102 months). Three partial responders to neoadjuvant VBM could have radical lymphadenectomy and they are alive disease-free 20, 27, 72 months after surgery. Two minimal responders could not have radical surgery and they died of the disease within one year.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2466471     DOI: 10.3109/02841868809094366

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  32 in total

Review 1.  Contemporary management of patients with penile cancer and lymph node metastasis.

Authors:  Andrew Leone; Gregory J Diorio; Curtis Pettaway; Viraj Master; Philippe E Spiess
Journal:  Nat Rev Urol       Date:  2017-04-11       Impact factor: 14.432

Review 2.  [Systemic therapy of penile cancer].

Authors:  E Preis; P Albers; G Jakse
Journal:  Urologe A       Date:  2006-05       Impact factor: 0.639

Review 3.  [Options in palliative therapy for penile cancer].

Authors:  E Preis; G Jakse
Journal:  Urologe A       Date:  2007-01       Impact factor: 0.639

Review 4.  Advanced penile cancer.

Authors:  Jonathan E Heinlen; David D Buethe; Daniel Joseph Culkin
Journal:  Int Urol Nephrol       Date:  2011-08-04       Impact factor: 2.370

5.  [Neoadjuvant, adjuvant and palliative chemotherapy of penile cancer].

Authors:  C Protzel; A K Seitz; O W Hakenberg; M Retz
Journal:  Urologe A       Date:  2013-11       Impact factor: 0.639

6.  Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study.

Authors:  Lance C Pagliaro; Dallas L Williams; Danai Daliani; Michael B Williams; William Osai; Michael Kincaid; Sijin Wen; Peter F Thall; Curtis A Pettaway
Journal:  J Clin Oncol       Date:  2010-07-12       Impact factor: 44.544

7.  Adjuvant pelvic radiation is associated with improved survival and decreased disease recurrence in pelvic node-positive penile cancer after lymph node dissection: A multi-institutional study.

Authors:  Dominic H Tang; Rosa Djajadiningrat; Gregory Diorio; Juan Chipollini; Zhenjun Ma; Braydon J Schaible; Mario Catanzaro; Dingwei Ye; Yao Zhu; Nicola Nicolai; Simon Horenblas; Peter A S Johnstone; Philippe E Spiess
Journal:  Urol Oncol       Date:  2017-06-27       Impact factor: 3.498

8.  [The current state of the art of chemotherapy of penile cancer: results of a nationwide survey of German clinics].

Authors:  C Protzel; S Ruppin; S Milerski; K-J Klebingat; O W Hakenberg
Journal:  Urologe A       Date:  2009-12       Impact factor: 0.639

9.  The risk factors for the presence of pelvic lymph node metastasis in penile squamous cell carcinoma patients with inguinal lymph node dissection.

Authors:  Jian-Ye Liu; Yong-Hong Li; Zhi-Ling Zhang; Kai Yao; Yun-Lin Ye; Dan Xie; Hui Han; Zhou-Wei Liu; Zi-Ke Qin; Fang-Jian Zhou
Journal:  World J Urol       Date:  2013-02-28       Impact factor: 4.226

Review 10.  Current trends in the management of carcinoma penis--a review.

Authors:  Iqbal Singh; A Khaitan
Journal:  Int Urol Nephrol       Date:  2003       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.